Amarin Corporation
-
Amarin Presents Key Eicosapentaenoic Acid (EPA) Mechanism Data at ESC 2025
Amarin Corporation presented new *in vitro* data at ESC Congress 2025 regarding VASCEPA®/VAZKEPA® (EPA). The research demonstrated EPA’s potential to reduce inflammation in atherosclerotic cardiovascular disease (ASCVD) by modulating the ATP-P2X7 axis and NLRP3 inflammasome in macrophages. Additionally, EPA inhibited lipoprotein(a) [Lp(a)] oxidation, mitigating oxidative stress and pro-inflammatory protein expression in endothelial cells. These findings suggest cardiovascular benefits of EPA may extend beyond triglyceride reduction, potentially offering further risk mitigation.
-
VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduces Hospitalizations & CVD Risk in High-Risk Patients: New REDUCE-IT® Analyses Presented at ESC 2025
Amarin Corporation presented REDUCE-IT® trial sub-analyses at ESC Congress 2025, highlighting the benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) regarding cardiovascular risk reduction. Key findings include a 9% drop in total hospitalizations and a 44% relative risk reduction in cardiovascular events for patients with Cardiovascular-Kidney-Metabolic (CKM) syndrome. The treatment also showed significant MACE reductions across all ApoB quartiles. The ESC/EAS guidelines reaffirmed icosapent ethyl as a Class IIA therapy.
